In 2022, results of important clinical trials have achieved for different subtypes of breast cancer. For the neo-adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer, the PHEDRA study provided new adjuvant treatment ...
2022年度欧洲肿瘤内科学会乳腺癌(线上)大会(2022 ESMO BreastCancer)于2022年5月3~5日在德国柏林举行。会议上,德国Kliniken Essen-Mitte研究院公布了一项名为monarchE试验队列1的疗效数据。 试验数据显示:阿贝西利(口服CDK4/6抑制剂)联合内分泌治疗(ET)作为HR+/HER2-高危早期乳腺癌(EBC)的术后辅助治疗表现出良好...
据日本就医网获悉:在2022年度欧洲肿瘤内科学会乳腺癌大会(2022 ESMO Breast Cancer,2022年5月3～5日,在线)上,西班牙巴塞罗那的HospitalClinic公布了多中心前瞻性试验SOLTITOT-HER3(A部分)的研究结果。 在未经治疗的激素受体阳性HER2阴性(HR+/HER2-)早期乳腺癌患者中,术前单次使用靶向HER3的ADC药物--patritumabderu...
据日本就医获悉:2022年度欧洲肿瘤内科学会乳腺癌(线上)大会(2022 ESMO BreastCancer)于2022年5月3~5日在德国柏林举行。会议上,德国Kliniken Essen-Mitte研究院公布了一项名为monarchE试验队列1的疗效数据。 试验数据显示:阿贝西利(口服CDK4/6抑制剂)联合内分泌治疗(ET)作为HR+/HER2-高危早期乳腺癌(EBC)的术后辅...
2022年圣安东尼奥乳腺癌研讨会于12月6~10日举行,Ⅲ期DESTINY-Breast02研究结果于会议上公布。试验数据显示:与医生选择的治疗(TPC)相比,T-DXd(Enhertu)在晚期HER2+不可切除和/或转移性乳腺癌患者中的死亡风险下降36%。T-DXd能够显着改善无进展生存期(PFS)和总生存期(OS)。
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol. 13, 228–241 (2016). Article CAS Google Scholar Disis, M. L. & Cecil, D. L. Breast cancer vaccines for treatment and prevention. Breast Cancer Res. Treat. 191, 481–489 (2022)...
Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402–421 (2022). Article PubMed Google Scholar Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463–479.e10 (2018). This study identifies four ...
Cancer Research 2011 Q2 Cancer Research 2012 Q2 Cancer Research 2013 Q2 Cancer Research 2014 Q2 Cancer Research 2015 Q2 Cancer Research 2016 Q2 Cancer Research 2017 Q3 Cancer Research 2018 Q2 Cancer Research 2019 Q2 Cancer Research 2020 Q3 Cancer Research 2021 Q3 Cancer Research 2022 Q2 Cancer Re...
Cancer vaccine is an attractive option as it aims to induce a durable immunologic response to eradicate tumor cells. Different types of breast cancer vaccines have been evaluated in clinical trials, but none has led to significant benefits. Despite the disappointing results at present, new promise ...
6. Nader-Marta G, et al. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open. 2022; 7:1. 7. Cortes J, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl...